Introduction:

Sickle Cell Disease Treatment Market was valued at US$ 3.3 Billion in 2024 and is projected to grow at a CAGR of 10.1% to reach US$ 7.8 Billion by 2034.

[PDF] Sickle Cell Disease Treatment Market is an inherited red blood cell disorders which affect hemoglobin that carries oxygen through body. Fatigue and shortness of breath are the main symptoms of sickle cell disease which can be fatal lead to organ damage and blocks flow of blood to organs. Stem cell and bone marrow transplant are the current treatment to cure Sickle Cell Disease.

Rising incidence of sickle cell disease has become the major contribution in target market growth. Further, according to CDC (Centers for Disease Control and Prevention), in United States (in 2022) the Sickle Cell Disease affects approx. 100,000 Americans, occurs among 1 out of every 365 Black or African-American births and around 1 in 13 Black or African-American babies are born with SCT (Sickle Cell Treat). Furthermore, emergence of new treatment in treating SCD is anticipated to boost the demand for Sickle Cell Disease Treatment market growth.

Rising incidence of SCD and demand for effective treatment

Rising incidence for SCD (Sickle Cell Disease) and demand for effective treatment has become the major factor in Sickle Cell Disease Treatment market growth. Further, according to CDC (Centers for Disease Control and Prevention), Sickle Cell Disease occurs among 1 out of every 16,300 Hispanic-American births. For instance, in 2022, according to PMC (PubMed Central), Sickle Cell Disease affect around 100,000 persons in U.S. with multiple complications and reduction in life expectancy. Furthermore, rising awareness of disease severity among individuals has given rise in demand for effective treatment procedures which has further facilitated the target market growth.

Emergence of new treatment modalities

Emergence of new treatment modalities has given positive impact on target market growth. Major players has increased their focus on launch of new products which has further facilitated the target market growth. For instance, in 2017, FDA (Food and Drug Administration) has approved Emmaus Life Sciences drug Endari for SCD patients who are aged around five years and old. After launch of Endari few more key players such as Oxbryta (Global Blood therapeutics), Zynteglo (bluebird bio Inc.), Adakveo (Novartis) and PYRUKYND (Agios Pharmaceuticals Inc.), emerged in market with launch of new products which is expected to fuel the demand for Sickle Cell Disease Treatment market growth.

Restrains:

However, slow adoption of treatments due to cost associated with it, absence of a permanent cure for this disease and complications associated with the treatment and high cost of drug has hampered the Sickle Cell Disease Treatment market growth.

Sickle Cell Disease Treatment Market is segmented based on Treatment Modality, End-User and Region.

Based on the Treatment Modality, Sickle Cell Disease Treatment market is segmented into the Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea, Branded Products {Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYNDN (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202})),Based on End-Users, the global market is classified into Hospitals, Specialty Clinics, and Others.

Regional Insights:

On the basis of region the Sickle Cell Disease Treatment Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to rising prevalence of SCD (Sickle Cell Disease), potential pipeline candidates, rising collaborations to improve treatment of disease, robust healthcare infrastructure and strong government initiative is anticipated to increase demand for Sickle Cell Disease Treatment in the region.

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Treatment Modality - Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy (Hydroxyurea, Branded Products {Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYNDN (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202})) By End-Users - Hospitals, Specialty Clinics, and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Sickle Cell Disease Treatment Market report based on Treatment Modality, End-Users and Region:

Sickle Cell Disease Treatment Market, By Treatment Modality:

• Bone Marrow Transplant
• Blood Transfusion
• Pharmacotherapy: 
  • Hydroxyurea
• Branded Products:
  • Endari
  • Adakveo
  • Oxbryta
  • Zynteglo
  • PYRUKYNDN (Mitapivat)
  • CTX001
  • Inclacumab
  • MGTA-145
  • Vamifeport (VIT-2763)
  • ALXN1820
  • FT-4202

Sickle Cell Disease Treatment Market, By End-Users:

• Hospitals
• Specialty Clinics
• Others

Sickle Cell Disease Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

Recent Development:

• In October 2022, Pfizer has completed the acquisition of Global Blood Therapeutics. This acquisition will bring the leading sickle cell disease portfolio & pipeline to Pfizer with potential for addressing critical needs in an underserved patient community. This acquisition will help in accelerating innovation, by expeditiously bringing multiple potential best-in-class treatment to people who are living with sickle cell disease.
• In September 2022, with rare acquisition, Novo Nordisk has made $1B bet on sickle cell disease drug. Novo Nordisk will spend $1.1 billion for acquiring Forma Therapeutics. This deal will reflect drug makers by continuing interest in sickle cell disease and related rare blood disorders.
• In April 2022, Emmaus Life Sciences has launched Full Service Telehealth Solution. This newly launched Telehealth solution in U.S. will afford patients and providers an online access to ‘Endari’ a company’s new prescription grade L-glutamine oral powder for treating sickle cell disease.

The key players operating the Sickle Cell Disease Treatment Market includes, Baxter, Bluebird Bio, Bristol-Myers Squibb Company, Eli Lilly, Global Blood Therapeutics, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Mast Therapeutics, Novartis AG, Pfizer, Inc., Sanofi and others.

• Pfizer, Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Baxter
• Bluebird Bio
• Bristol-Myers Squibb Company
• Eli Lilly
• Global Blood Therapeutics
• Gilead Sciences, Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Mast Therapeutics
• Novartis AG
• Sanofi

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Treatment Modality
     • Market Snippet, By End-Users
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Sickle Cell Disease Treatment Market, By Treatment Modality
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Bone Marrow Transplant
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Blood Transfusion
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Pharmacotherapy
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
6. Sickle Cell Disease Treatment Market, By End-Users, 2022 – 2032, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Segment Trends
   • Hospitals
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Specialty Clinics
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
   • Others
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
7. Sickle Cell Disease Treatment Market, By Region, 2022 – 2032, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
     • Y-o-Y Growth Analysis (%), 2022 – 2032
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Treatment Modality, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Treatment Modality, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Treatment Modality, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
     • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific

• • Latin America
    • Market Size and Forecast (US$ Bn), By Treatment Modality, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
• • • • Brazil
      • Mexico
      • Rest of Latin America
  • Middle East & Africa
    • Market Size and Forecast (US$ Bn), By Treatment Modality, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
    • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032

1. • • • GCC
       • Israel
       • South Africa
       • Rest of Middle East
2. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
3. Company Profiles

• Baxter
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bluebird Bio
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eli Lilly
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Global Blood Therapeutics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Gilead Sciences, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Mast Therapeutics
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sanofi
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact